# A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)

> **NCT00485589** · PHASE3 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 613 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Ocrelizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00485589
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06-11
- **Primary completion:** 2010-01-29
- **Final completion:** 2013-08-29
- **Target enrollment:** 613 (ACTUAL)
- **Why stopped:** Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.
- **Last updated:** 2020-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00485589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00485589, "A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00485589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*